Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6* 6 and* 26
H Gatanaga, T Hayashida, K Tsuchiya… - Clinical infectious …, 2007 - academic.oup.com
Background. Efavirenz (EFV) is metabolized primarily by cytochrome P450 2B6 (CYP2B6),
and high plasma concentrations of the drug are associated with a G→ T polymorphism at …
and high plasma concentrations of the drug are associated with a G→ T polymorphism at …
[PDF][PDF] Impact of gender, weight and CYP2B6 genotype on efavirenz exposure in patients on HIV/AIDS and TB treatment: Implications for individualising therapy
T Nemaura, C Nhachi… - African Journal of …, 2012 - academicjournals.org
Gender, weight and cytochrome P450 2B6 (CYP2B6) 516G> T genetic data of 61 patients
on efavirenz containing highly active anti-retroviral therapy (HAART) was collated and …
on efavirenz containing highly active anti-retroviral therapy (HAART) was collated and …
Pharmacogenetics of Efavirenz response in Bantu-speaking South African HIV/AIDS patients
M Swart - 2011 - open.uct.ac.za
Efavirenz (EFV) is used in first-line antiretroviral (ARV) therapy of HIV-infected patients, and
is principally metabolised by CYP1A2, CYP2A6, CYP2B6, CYP3A4/5 and the drug …
is principally metabolised by CYP1A2, CYP2A6, CYP2B6, CYP3A4/5 and the drug …
Impact of CYP2B6 and CYP2A6 polymorphisms on efavirenz plasma concentrations in Ghanaian HIV-infected patients
Y Zhang, A Owen, D Egan, SF Sarfo - Journal of the International AIDS …, 2010 - Springer
Methods Following informed consent, blood samples were obtained from 521 adults on
efavirenz based ART. Drug concentrations approximately 12-14h post-dose were measured …
efavirenz based ART. Drug concentrations approximately 12-14h post-dose were measured …
Impact of Pharmacogenetic Markers of CYP2B6, Clinical Factors, and Drug-Drug Interaction on Efavirenz Concentrations in HIV/Tuberculosis-Coinfected Patients
W Manosuthi, C Sukasem… - Antimicrobial agents …, 2013 - Am Soc Microbiol
Comprehensive information on the effects of cytochrome P450 2B6 (CYP2B6)
polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in …
polymorphisms, clinical factors, and drug-drug interactions on efavirenz concentrations in …
[HTML][HTML] CYP2B6 516 G>T polymorphism and side effects of the central nervous system in HIV-positive individuals under Efavirenz treatment: Study of a sample from …
TE Mueller, JH Ellwanger, RT Michita… - Anais da Academia …, 2017 - SciELO Brasil
This study aimed to identify the 516 G> T polymorphism of the CYP2B6 gene and evaluate
its influence on central nervous system (CNS) side effect development in HIV-positive …
its influence on central nervous system (CNS) side effect development in HIV-positive …
The role of genetic polymorphisms in cytochrome P450 and effects of tuberculosis co-treatment on the predictive value of CYP2B6 SNPs and on efavirenz plasma …
Efavirenz (EFV) exhibits interindividual pharmacokinetic variability caused by differences in
cytochrome P450 (CYP) expression. Most tuberculosis (TB) drugs interact with the CYP …
cytochrome P450 (CYP) expression. Most tuberculosis (TB) drugs interact with the CYP …
[引用][C] Long-term efavirenz pharmacokinetics is comparable between Tanzanian HIV and HIV/Tuberculosis patients with the same CYP2B6* 6 genotype
E Ngaimisi - 2018 - Deutsche Nationalbibliothek
Polymorphisms in cytochrome P450 are associated with extensive efavirenz pharmacokinetics and CNS toxicities in an HIV cohort in Botswana
M Vujkovic, SL Bellamy, AF Zuppa… - The …, 2018 - nature.com
Inter-individual variability in efavirenz (EFV) pharmacokinetics and dynamics is dominantly
driven by the polymorphism in cytochrome P450 (CYP) isoenzyme 2B6 516G> T. We …
driven by the polymorphism in cytochrome P450 (CYP) isoenzyme 2B6 516G> T. We …
Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin …
Objectives Plasma efavirenz concentrations in HIV-infected patients with tuberculosis (TB)
may be affected by cytochrome P450 (CYP) 2B6 single-nucleotide polymorphisms and …
may be affected by cytochrome P450 (CYP) 2B6 single-nucleotide polymorphisms and …